| Literature DB >> 21180465 |
Abstract
OBJECTIVE: Fast dissolving drug delivery system offers a solution for those patients having difficulty in swallowing tablets/capsules etc. Verapamil is a calcium channel blocker used as an antianginal, antiarrhythmic, and antihypertensive agent with extensive first pass metabolism which results in less bioavailability. This work investigated the possibility of developing verapamil fast dissolving strips allowing fast, reproducible drug dissolution in the oral cavity; thus bypassing first pass metabolism.Entities:
Keywords: Fast dissolving strips; HPMC E6; maltodextrin; verapamil
Year: 2010 PMID: 21180465 PMCID: PMC2996061 DOI: 10.4103/0975-7406.72133
Source DB: PubMed Journal: J Pharm Bioallied Sci ISSN: 0975-7406
Formulation of fast dissolving strip of verapamil hydrochloride
| Ingredients | F1 (%) | F2 (%) | F3 (%) | F4 (%) | F5 (%) |
|---|---|---|---|---|---|
| HPMC E6 | 2 | 2 | 2 | 5 | 2 |
| Maltodextrin | 1 | 2.5 | 3.5 | 2.5 | - |
| Glycerol | 15 | 15 | 15 | 15 | 15 |
| Aspartame | 7 | 7 | 7 | 7 | 7 |
| Flavorant raspberry | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Sodium benzoate | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Colorant amaranth | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Distilled water | qs | qs | qs | qs | qs |
Quantities are expressed in terms of w/v.
Quantities are expressed in terms of w/w of polymer
Figure 1Standard curve of verapamil in phosphate buffer pH 6.6
Figure 2UV-spectrum of verapamil
Key for the evaluation of palatability study
| Parameter | Taste | After bitterness | Mouth feel |
|---|---|---|---|
| 0 | Not good | Not bitter | Not good |
| + | Good | Slightly bitter | Good |
| ++ | Very good | Bitter Very | good |
| +++ | Excellent | Very bitter | Excellent |
Evaluation of fast dissolving strip of verapamil hydrochloride
| Formulation code | Drug content (%) | Film thickness (mm) | Folding endurance | Disintegration time (seconds) | Surface pH |
|---|---|---|---|---|---|
| F1 | 99.31±1.09 | 0.328±0.01 | 271.667±0.57 | 24.667±0.57 | 6.91±0.08 |
| F2 | 100.78±0.5 | 0.2267±0.01 | 298.334±2.08 | 23±3.21 | 6.73±0.21 |
| F3 | 100.49±1.63 | 0.206±0.005 | 300±1 | 20.334±1 | 6.913±0.08 |
| F4 | 99.36±1.11 | 0.295±0.01 | 262.667±2.51 | 28.667±0.57 | 6.86±0.1 |
| F5 | 100.17±0.26 | 0.24±0.01 | 257.334±1.52 | 27±1 | 6.85±0.07 |
Results are expressed in terms of mean ± SD (n = 3).
Figure 3In-vitro drug release profile of formulations from F1 to F5
Results of in-vivo performance of fast dissolving oral strips of batches F1 to F5 (n = 6)
| Formulation Code | Palatability Study | ||
|---|---|---|---|
| Taste | After bitterness | Mouth feel | |
| F1 | +++ | 0 | ++ |
| F2 | ++ | + | +++ |
| F3 | +++ | 0 | +++ |
| F4 | + | ++ | ++ |
| F5 | ++ | + | ++ |